CLECL1 (C-type lectin like 1) functions as a signaling receptor involved in immune cell regulation and cancer progression. The protein demonstrates immune-modulatory functions, with evidence showing positive association with CD4+ T cell infiltration in lung adenocarcinoma 1. CLECL1 serves as a prognostic biomarker across multiple cancer types, being identified as a key gene in tumor-associated macrophage signatures for head and neck squamous cell carcinoma prognosis 2 and as part of prognostic gene panels for lung adenocarcinoma survival prediction 34. In cardiovascular disease, CLECL1 appears as a hub gene specifically associated with infrapopliteal atherosclerosis, distinguishing it from atherosclerosis in other arterial beds 5. The gene also shows relevance in autoimmune disease, with genetic variants colocalizing with type 1 diabetes risk loci and monocyte expression quantitative trait loci, suggesting a role in pancreatic beta-cell autoimmune destruction 6. While the precise molecular mechanisms remain incompletely characterized, CLECL1's consistent emergence in immune-related pathways and disease contexts indicates its importance in immune cell function and pathological processes.